388 related articles for article (PubMed ID: 35174450)
1. The hub ten gene-based risk score system using RNA m
Yuan B; Liu W; Huo M; Zhang J; Yang Y; Gao T; Yin X; Yang T; Teng X; Huang W; Yu H
Breast Cancer; 2022 Jul; 29(4):645-658. PubMed ID: 35174450
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
4. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
6. m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer.
Sheng G; Wang T; Gao Y; Wu H; Wu J
Sci Rep; 2023 Nov; 13(1):19670. PubMed ID: 37952076
[TBL] [Abstract][Full Text] [Related]
7. RNA N6-Methyladenosine Regulators Contribute to Tumor Immune Microenvironment and Have Clinical Prognostic Impact in Breast Cancer.
Mu LX; Shao YC; Wei L; Chen FF; Zhang JW
Front Genet; 2021; 12():650499. PubMed ID: 35095993
[No Abstract] [Full Text] [Related]
8. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of N6-Methyladenosine (m
Liu D; Yuan M; Wang Z; Sun L; Fang Y; Ma X; Zhang L; Xing Y; Zhu J; Liu Y; Zhu W; Bao S; Jia Y; Wang Y
Can J Gastroenterol Hepatol; 2022; 2022():3506518. PubMed ID: 36452120
[TBL] [Abstract][Full Text] [Related]
10. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.
Li L; Yang W; Jia D; Zheng S; Gao Y; Wang G
Breast Cancer; 2023 Jul; 30(4):666-684. PubMed ID: 37178414
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
13. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
14. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
15. The N6-methyladenosine methylation landscape stratifies breast cancer into two subtypes with distinct immunological characteristics.
Chen Y; Hou Y; Li S; Qin W; Zhang J
Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13875. PubMed ID: 38797522
[TBL] [Abstract][Full Text] [Related]
16. m
Chong W; Shang L; Liu J; Fang Z; Du F; Wu H; Liu Y; Wang Z; Chen Y; Jia S; Chen L; Li L; Chen H
Theranostics; 2021; 11(5):2201-2217. PubMed ID: 33500720
[TBL] [Abstract][Full Text] [Related]
17. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
18. Novel RNA N6-methyladenosine regulator related signature for predicting clinical and immunological characteristics in breast cancer.
Zhang J; Liu G; Dai Z; Xie F; Zheng R; Yuan B; Guo L
Gene; 2023 Feb; 853():147095. PubMed ID: 36464173
[TBL] [Abstract][Full Text] [Related]
19. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
[TBL] [Abstract][Full Text] [Related]
20. m
Wen Q; Wang S; Hong L; Shen S; He Y; Sheng X; Zhuang X; Chen S; Wang Y; Zhuang H
Immun Inflamm Dis; 2024 Jan; 12(1):e1150. PubMed ID: 38270308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
